No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
www.ono-pharma.comNo one on the platform currently holds 4528.T.
No tracked institution reports a position in 4528.T as of their last filing.
No one on the platform has traded 4528.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.6% | 14.2% | 12.7% | — | — | — |
| Rev. Growth % | 5.9% | 10.8% | ||||
| Profit Margin % | 13.5% | 19.4% | 20.1% | |||
| Free Cash Flow Margin % | 25.4% | 22.5% | 19.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $458.2B | -9.5% | $155.02 | $126.96–$171.75 | — | 11 |
| 2028 | $448.5B | -2.1% | $137.37 | $112.85–$154.14 | — | 11 |
| 2029 | $460.8B | +2.7% | $145.85 | $110.92–$180.02 | — | 10 |
| 2030 | $480.3B | +4.2% | $155.72 | $148.29–$164.43 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $33.74 | $51.40 | +52.3% |
| 2026-05-08 | $8.25 | $1.74 | -78.9% |
| 2026-02-02 | $45.26 | $61.42 | +35.7% |
| 2025-10-30 | $40.65 | $47.71 | +17.4% |
| 2025-08-01 | $49.47 | $37.62 | -24.0% |
| 2025-05-08 | $13.83 | $-13.94 | -200.8% |
| 2025-02-03 | $52.05 | $31.83 | -38.8% |
| 2024-10-31 | $50.88 |
| $35.87 |
| -29.5% |
| +1.55% |
| $1.17T |
| — |
| 4506.TSumitomo Pharma Co., Ltd. | $1567.50 | +2.65% | $703.2B | — |
| 4523.TEisai Co., Ltd. | $4743.00 | +1.82% | $1.34T | — |
Source: Financial Modeling Prep · peers by sector/industry